List of Excipients in Branded Drug DENAVIR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mylan Pharmaceuticals Inc	DENAVIR	penciclovir	0378-9720	CETOSTEARYL ALCOHOL
Mylan Pharmaceuticals Inc	DENAVIR	penciclovir	0378-9720	MINERAL OIL
Mylan Pharmaceuticals Inc	DENAVIR	penciclovir	0378-9720	PETROLATUM
Mylan Pharmaceuticals Inc	DENAVIR	penciclovir	0378-9720	POLYOXYL 20 CETOSTEARYL ETHER

Denavir Excipient Strategy and Commercial Opportunities for Penciclovir Cream

Last updated: August 19, 2026

Denavir is a prescription 1% penciclovir cream for recurrent herpes labialis, commonly called cold sores. Its formulation uses a conventional topical cream base built around propylene glycol, mineral oil, white petrolatum, cetostearyl alcohol, and purified water. The commercial opportunity is no longer based on compound exclusivity. It lies in differentiated delivery, improved cosmetic performance, consumer adherence, preservative strategy, expanded distribution, and potentially nonprescription positioning.

What is Denavir and how is it regulated?

Denavir contains penciclovir 1% for topical treatment of recurrent herpes labialis in adults and pediatric patients aged 12 years and older. The labeled regimen is application every two hours during waking hours for four days. Treatment should begin as early as possible after symptoms appear.[1]

Attribute	Denavir
Active ingredient	Penciclovir
Strength	1% cream
Dosage form	Topical cream
U.S. indication	Recurrent herpes labialis
Labeled population	Adults and patients aged 12 years and older
Application	Every two hours while awake for four days
Regulatory status	Prescription drug
FDA application	NDA 020629
Primary commercial category	Topical antiviral
Main competitors	Acyclovir cream, docosanol cream, generic penciclovir cream, oral antivirals

Denavir is not an over-the-counter product. By contrast, docosanol 10% cream is marketed in the U.S. as an OTC cold-sore treatment. That difference creates both a competitive disadvantage and a potential lifecycle-management opportunity.

What excipients are used in Denavir cream?

The Denavir formulation uses a water-in-oil or emulsion-based topical cream system intended to deliver penciclovir across the lip and perioral skin while maintaining acceptable spreadability.

The FDA labeling identifies the following inactive ingredients:

Excipient	Likely formulation function
Propylene glycol	Solvent, humectant, and skin-penetration aid
Mineral oil	Emollient and oil-phase vehicle
White petrolatum	Occlusive emollient and consistency agent
Cetostearyl alcohol	Emulsifying, thickening, and stabilizing agent
Purified water	Aqueous phase and vehicle

The formulation is relatively simple. It does not depend on a complex polymeric delivery system, liposome, nanoparticle, or transdermal patch. This simplicity reduces manufacturing complexity but also limits differentiation from generic penciclovir cream.

What role does propylene glycol play?

Propylene glycol is the most strategically important excipient in the Denavir formulation. It can improve penciclovir solubilization, support drug partitioning into the stratum corneum, and reduce water loss from the skin.

Its limitations are equally important. Propylene glycol can cause irritation or sensitization in some users, particularly when applied to inflamed or fissured skin. A reformulation that reduces propylene glycol while preserving penciclovir delivery could support a premium product claim based on tolerability.

Why are mineral oil and white petrolatum important?

Mineral oil and white petrolatum provide occlusion and emollience. These excipients can reduce dryness and improve the feel of a cream applied to the lips or perioral area.

Their commercial disadvantages include greasiness, visible residue, and lower compatibility with makeup or rapid reapplication. A less greasy, rapidly absorbing vehicle could improve adherence during the four-day dosing period.

What does cetostearyl alcohol contribute?

Cetostearyl alcohol is a fatty alcohol used to thicken and stabilize topical emulsions. It is not the same as ethanol and is generally used to produce a smooth cream structure.

Its presence can create a potential labeling issue for patients with sensitivity to fatty alcohols, although the clinical significance differs from allergy to simple alcohols. A new formulation could replace or reduce cetostearyl alcohol with alternative emulsifiers, provided the new base maintains stability, spreadability, and preservative protection.

What formulation patents protect Denavir?

The original commercial value of Denavir came from penciclovir and its clinical use, not from a highly complex excipient platform. Penciclovir compound and antiviral-use patents were filed decades before the current market period and are no longer the primary source of commercial exclusivity.

The relevant IP categories are now:

1. Penciclovir topical composition patents.
2. Cream-base and drug-delivery patents.
3. Particle-size or solubilization patents.
4. Film-forming formulations.
5. Combination products containing penciclovir.
6. Method-of-use patents covering treatment timing or patient subgroups.
7. Packaging and unit-dose delivery systems.
8. Manufacturing processes for improving content uniformity or stability.

A new formulation patent would need a specific technical distinction. A patent covering only the use of conventional excipients at routine concentrations would face a significant obviousness risk. Stronger claims could arise from:

• A defined penciclovir solubilization system with improved skin deposition.
• A low-irritancy vehicle with reduced propylene glycol exposure.
• A film-forming formulation that increases residence time on the lip.
• A formulation with measurable improvement in lesion healing or pain reduction.
• A unit-dose or applicator system that reduces contamination and improves dosing.
• A stable anhydrous or preservative-free composition.
• A pediatric formulation with improved tolerability and adherence.

When does Denavir lose exclusivity?

Denavir's original regulatory and compound exclusivity periods have expired. Penciclovir is an established antiviral active ingredient, and generic competition has been possible through abbreviated regulatory pathways.

The key commercial protection is therefore not a current compound patent. It is the combination of brand recognition, physician familiarity, retail access, product presentation, and any remaining formulation or regulatory rights.

Protection category	Commercial position
Original compound protection	Expired
Original method-of-use protection	Expired or commercially immaterial
New chemical entity exclusivity	Expired
Current product differentiation	Brand, formulation, packaging, distribution
Biosimilar protection	Not applicable
Generic substitution risk	Relevant
OTC competitor pressure	High from docosanol products

What is the Orange Book status of Denavir?

Denavir is associated with FDA-approved NDA 020629. The Orange Book is the relevant source for current patent and exclusivity listings, therapeutic equivalence codes, and approved product information.[2]

For commercial analysis, the principal point is that Denavir does not have the protection profile of a recently approved small-molecule product. Any current Orange Book patent listing would need to be evaluated claim by claim for expiration, pediatric applicability, and enforceability. The practical competitive threat comes from approved generic penciclovir cream and alternative cold-sore products rather than biosimilars.

A generic applicant could use an abbreviated new drug application if it can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA requirements for the topical product. For a topical cream, formulation differences can create regulatory and development complexity even when the active ingredient and strength are identical.

What generic entry risks exist for Denavir?

Generic entry risk is material because the product has:

• A known active ingredient.
• A simple topical dosage form.
• A mature indication.
• No biologic manufacturing barrier.
• No meaningful biosimilar barrier.
• Multiple potential cream-base alternatives.

Generic penciclovir products can compete on price while relying on the same active ingredient and indication. Substitution risk will depend on state pharmacy rules, payer formularies, product availability, and whether the generic achieves therapeutic equivalence under the FDA's current classification.

What could delay or limit generic competition?

The principal barriers are technical rather than patent-based:

• Demonstrating equivalent drug release from the cream matrix.
• Matching the reference product's physical characteristics.
• Establishing stability across temperature conditions.
• Controlling penciclovir particle size and distribution.
• Showing equivalent active-ingredient availability at the skin surface.
• Maintaining microbial quality without an irritating preservative system.
• Achieving commercial-scale content uniformity.

These barriers can support a formulation-development business, but they are unlikely to preserve long-term brand exclusivity by themselves.

Which excipient strategies offer the strongest commercial opportunities?

1. Low-irritancy reformulation

A propylene-glycol-reduced or propylene-glycol-free cream could target users who experience stinging or irritation. The development objective would be to preserve penciclovir solubilization and skin delivery through alternative solvents, co-solvents, or emulsion architecture.

Commercial positioning could include sensitive-skin use, improved comfort, and better suitability for repeated application.

2. Fast-drying film-forming cream

A film-forming system could increase residence time on the lip and reduce removal from eating, drinking, or licking. Candidates may include selected acrylate polymers, cellulose derivatives, polyvinyl alcohol systems, or other dermatologically acceptable film formers.

The product would need to avoid cracking, whitening, tackiness, and an unnatural appearance. A film-forming system is commercially attractive only if it improves adherence without reducing cosmetic acceptability.

3. Non-greasy cream or gel-cream

Replacing part of the mineral oil and petrolatum phase with lighter emollients, volatile carriers, or a structured gel system could produce a product with faster absorption and less residue.

The central technical risk is reduced drug solubilization or altered release. A successful product would need comparative data showing equivalent or improved penciclovir delivery.

4. Preservative-free or low-preservative packaging

Single-use sachets, metered-dose pumps, airless tubes, and unit-dose applicators could reduce contamination risk and support preservative reduction.

Packaging can also create a separate patent opportunity. Claims may focus on a container that dispenses a controlled amount of cream, prevents backflow, or protects the formulation from air and moisture.

5. Pediatric and adolescent formulation

The current label includes patients aged 12 years and older. A formulation with improved taste avoidance, lower residue, and easier application could support adherence in adolescents.

A true pediatric expansion would require FDA review and clinical or regulatory support. The commercial opportunity is more realistic as a formulation and packaging program unless a sponsor pursues a new indication or age expansion.

How does Denavir compare with competing cold-sore treatments?

Product category	Active ingredient	Status	Main advantage	Main weakness
Denavir	Penciclovir 1%	Prescription	Established topical antiviral	Frequent dosing and prescription access
Generic penciclovir	Penciclovir 1%	Prescription	Lower price	Limited brand differentiation
Acyclovir cream	Acyclovir 5%	Prescription	Familiar antiviral	Similar topical-use limitations
Docosanol cream	Docosanol 10%	OTC	Immediate consumer access	Different mechanism and efficacy profile
Oral antivirals	Acyclovir, valacyclovir, famciclovir	Prescription	Systemic treatment and convenient regimens	Requires oral dosing and clinical prescribing

Denavir's main formulation opportunity is to reduce the burden of frequent application. A product applied less often, retained longer, or packaged for faster use could compete on convenience rather than active-ingredient novelty.

What licensing and partnership opportunities exist?

Potential partners include:

• Generic manufacturers seeking a differentiated penciclovir platform.
• Consumer-health companies with OTC dermatology distribution.
• Contract development and manufacturing organizations with topical expertise.
• Packaging companies developing unit-dose or metered applicators.
• Specialty dermatology companies with prescription sales infrastructure.
• Digital pharmacy and telehealth platforms focused on episodic herpes labialis treatment.

A licensing package would be stronger if it included comparative skin-delivery data, irritation testing, stability data, and a defined regulatory pathway. A simple excipient substitution without clinical or biopharmaceutic differentiation would have limited licensing value.

What is the revenue exposure and market outlook?

Public product-level revenue for Denavir is not generally disclosed separately from broader company portfolios. Revenue exposure is likely constrained by generic penciclovir availability, OTC substitution, prescription access, and the short duration of treatment.

The commercial model has three viable directions:

1. Defend the existing prescription brand through convenience and tolerability.
2. License a differentiated topical platform to a generic or consumer-health company.
3. Develop a reformulated product for broader nonprescription distribution, subject to FDA requirements.

The strongest near-term opportunity is a premium topical product that improves cosmetic performance and reduces application friction. The weakest opportunity is an undifferentiated cream with the same active ingredient and conventional excipients.

Key Takeaways

• Denavir is a prescription penciclovir 1% cream for recurrent herpes labialis.
• Its core excipients are propylene glycol, mineral oil, white petrolatum, cetostearyl alcohol, and purified water.
• Compound and original product exclusivity are no longer the main commercial defenses.
• Generic entry and OTC docosanol competition create substantial price and access pressure.
• The most credible formulation opportunities are low-irritancy, fast-drying, film-forming, non-greasy, preservative-reduced, and unit-dose products.
• A new patent position would require measurable technical or clinical differentiation.
• Biosimilar risk is not relevant because Denavir is a small-molecule topical drug.
• Licensing value depends on comparative delivery, tolerability, stability, packaging, and regulatory data.

FAQs

Can Denavir excipients be changed without a new FDA application?

A material formulation change generally requires regulatory assessment and may require submission under an approved application or a new application, depending on the nature and extent of the change.

Is propylene glycol essential to penciclovir cream performance?

It is not necessarily essential, but it is an important solvent and penetration-support excipient. Replacing it requires evidence that drug release, skin delivery, stability, and tolerability remain acceptable.

Can a penciclovir cream become an OTC product?

Potentially, but an OTC switch would require FDA review of the active ingredient, labeling, safety, consumer comprehension, and conditions of use. Denavir's current prescription status does not establish OTC eligibility.

Are there biosimilars to Denavir?

No. Denavir contains penciclovir, a small-molecule antiviral. Competitive products are generics or alternative antiviral products, not biosimilars.

What is the strongest patent strategy for a new penciclovir product?

The strongest strategy would combine composition claims with data-supported claims covering improved skin residence, reduced irritation, controlled delivery, packaging performance, or a clinically meaningful improvement in treatment outcomes.

References

1. U.S. Food and Drug Administration. (n.d.). Denavir (penciclovir) cream, 1%: Prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. National Library of Medicine. (n.d.). Denavir- penciclovir cream. DailyMed. https://dailymed.nlm.nih.gov/dailymed/

4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application requirements for topical dermatological drug products. FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-bioequivalence-recommendations